Chevaliez Stéphane, Pawlotsky Jean-Michel
Department of Virology, INSERM U635, Henri Mondor Hospital, University of Paris XII, Créteil, France.
Int J Med Sci. 2006;3(2):35-40. doi: 10.7150/ijms.3.35. Epub 2006 Apr 1.
The use of serological and virological tests has become essential in the management of hepatitis C virus (HCV) infection in order to diagnose infection, guide treatment decisions and assess the virological response to antiviral therapy. Virological tools include serological assays for anti-HCV antibody detection and serological determination of the HCV genotype, and molecular assays that detect and quantify HCV RNA and determine the HCV genotype. Anti-HCV antibody testing and HCV RNA testing are used to diagnose acute and chronic hepatitis C. Only patients with detectable HCV RNA should be considered for pegylated interferon alfa and ribavirin therapy and the HCV genotype should be systematically determined before treatment, as it determines the indication, the duration of treatment, the dose of ribavirin and the virological monitoring procedure. HCV RNA monitoring during therapy is used to tailor treatment duration in HCV genotype 1 infection, and molecular assays are used to assess the end-of-treatment and, most importantly the sustained virological response, i.e. the endpoint of therapy.
血清学和病毒学检测在丙型肝炎病毒(HCV)感染的管理中已变得至关重要,以便诊断感染、指导治疗决策并评估对抗病毒治疗的病毒学反应。病毒学工具包括用于检测抗-HCV抗体的血清学检测方法以及HCV基因型的血清学测定,还有检测和定量HCV RNA并确定HCV基因型的分子检测方法。抗-HCV抗体检测和HCV RNA检测用于诊断急性和慢性丙型肝炎。只有HCV RNA可检测到的患者才应考虑接受聚乙二醇化干扰素α和利巴韦林治疗,并且在治疗前应系统地确定HCV基因型,因为它决定了治疗指征、治疗持续时间、利巴韦林剂量以及病毒学监测程序。治疗期间的HCV RNA监测用于调整HCV基因型1感染的治疗持续时间,分子检测方法用于评估治疗结束时的情况,最重要的是评估持续病毒学应答,即治疗终点。